Home > Neurology > EAN 2021 > Epilepsy > Good safety and efficacy of cenobamate for focal seizures

Good safety and efficacy of cenobamate for focal seizures


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
EAN 2021
Trial
C013, C017, C021
Onset of cenobamate efficacy in patients with uncontrolled focal seizures occurred early, occurred at lower doses than the target dose for maintenance therapy, and continued to improve at higher doses [1]. Adverse events (AEs) occurred primarily during titration, were generally self-limited in duration, and mainly mild or moderate in severity [2]. Slower titration reduced their severity. In Europe, cenobamate is approved for the adjunctive treatment of focal-onset seizures with or without secondary generalisation, in adult patients who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic drugs. In C013 (NCT01397968) [3] and C017 (NCT01866111) [4], 2 international, double-blind, placebo-controlled trials with open-label extensions...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on